This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aetna Inks Deals to Improve Patient Care in Philadelphia
by Zacks Equity Research
Aetna (AET) collaborates with Oak Street Health and ChenMed for enhancing the experience of its Medicare members in the Philadelphia market.
Cigna Moves Closer to Express Scripts Buyout With DoJ Nod
by Zacks Equity Research
Cigna (CI) clears a significant regulatory hurdle with regards to its proposed acquisition of Express Scripts.
Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake
by Zacks Equity Research
Abbott (ABT) to see a rise in customer adoption of its DRG therapy following the receipt of new national coverage from Aetna.
Molina Healthcare Surges 80% YTD: Can the Rally Continue?
by Zacks Equity Research
Molina Healthcare (MOH) gains from its rebounding endeavors and a niche positioning in the Medicaid market.
Anthem Ties Up With Walmart to Better Serve Medicare Members
by Zacks Equity Research
Anthem (ANTM) teams up with Walmart to provide medical supplies across its counter.
Aetna (AET) Reaches 52-Week High on a Solid Second Quarter
by Zacks Equity Research
Aetna's (AET) shares scale a 52-week high on Aug 17, 2018 led by strong second-quarter performance.
Aetna Launches Scheme for Better Patient Care Amenities
by Zacks Equity Research
Aetna (AET) proposes a new regional plan to serve employers better.
UnitedHealth to Spread in Pharmacy Business With Genoa Deal
by Zacks Equity Research
UnitedHealth's (UNH) acquisition of Genoa Health should aid the company's Optum segment.
Molina Healthcare Hits 52-Week High: Is Further Upside Left?
by Zacks Equity Research
Molina Healthcare (MOH) stock gains as its restructuring initiatives start bearing fruit.
Envision Healthcare (EVHC) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Envision Healthcare (EVHC) Q2 earnings were backed by higher contribution from its segments.
Q2 Scorecard & Research Reports for Gilead, American Tower & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), American Tower (AMT) and Chubb (CB).
Aetna (AET) Q2 Earnings Beat Estimates, Membership Declines
by Zacks Equity Research
Aetna's (AET) Q2 earnings gained from a lower tax rate partly offset by increase in expenses.
Aetna (AET) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Aetna (AET) delivered earnings and revenue surprises of 11.73% and 0.83%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will a Decline in Membership Mar Aetna's (AET) Q2 Earnings?
by Zacks Equity Research
Aetna (AET) Q2 earnings to suffer from lower membership and revenues partly offset by a lower tax rate.
How Will Membership Affect UnitedHealth's (UNH) Q2 Earnings?
by Zacks Equity Research
UnitedHealth (UNH) should see an increase in Public Group and International business, partially offset by lower commercial membership.
UnitedHealth's Unit to Provide Better Care in North Carolina
by Zacks Equity Research
UnitedHealth's (UNH) arm forges an alliance with Community Care for providing better and cost-efficient care in North Carolina.
The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna
4 Reasons That Make WellCare Health Plans an Attractive Pick
by Zacks Equity Research
WellCare Health Plans (WCG) looks attractive given its promising growth prospects.
Will Insurers Suffer on Halt in Risk-Adjustment Payment?
by Sapna Bagaria
The most-recent regulatory action to halt risk-adjustment payments should pose uncertainty for health insurers.
Top Research Reports for Mastercard, Gilead & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Gilead (GILD) and Goldman Sachs (GS).
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
LabCorp, Philips Tie Up to Advance in Digital Pathology
by Zacks Equity Research
Through the latest collaboration, LabCorp (LH) aims at strengthening its hold inthe high potential digital pathology market.
UnitedHeathcare Arm Gets Charge of Kansas Medicaid Program
by Zacks Equity Research
The State of Kansas picks UnitedHealth Group (UNH) arm for administering the statewide Medicaid Program.
Want to Tap Merger Mania? Play Top-Ranked Health Care ETFs
by Sanghamitra Saha
What is driving Healthcare merger-mania and how to tap it with ETFs.
Rite Aid-Albertsons Deal: US SEC Sanctions Proxy Materials
by Zacks Equity Research
Rite Aid (RAD) is moving closer to completing its previously announced merger with Albertsons. The company's shareholders are going to cast their votes regarding the deal on Aug 9.